Hydroxychloroquine in Blocking Autophagy in Patients With Prostate Cancer Undergoing Surgery or Active Surveillance
Status:
Terminated
Trial end date:
2016-02-26
Target enrollment:
Participant gender:
Summary
This phase 0 trial studies hydroxychloroquine in blocking autophagy in patients with prostate
cancer who are undergoing surgery or active surveillance. Autophagy is a process in which
cells break down some parts of themselves to stay alive during times of stress, such as
starvation. This may allow cancer cells to survive damage from chemotherapy.
Hydroxychloroquine may block this process from happening.
Phase:
Early Phase 1
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborators:
National Cancer Institute (NCI) Rutgers Cancer Institute of New Jersey